Upsher Smith Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UPSHER SMITH, and when can generic versions of UPSHER SMITH drugs launch?
UPSHER SMITH has ninety-seven approved drugs.
There are eight US patents protecting UPSHER SMITH drugs.
There are seventeen patent family members on UPSHER SMITH drugs in ten countries and one hundred and forty-two supplementary protection certificates in fourteen countries.
Summary for Upsher Smith
| International Patents: | 17 |
| US Patents: | 8 |
| Tradenames: | 74 |
| Ingredients: | 68 |
| NDAs: | 97 |
Drugs and US Patents for Upsher Smith
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | MYORISAN | isotretinoin | CAPSULE;ORAL | 076485-002 | Jan 19, 2012 | AB1 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-005 | Mar 11, 2014 | AB2 | RX | Yes | Yes | 8,889,190 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Upsher Smith Labs | JANTOVEN | warfarin sodium | TABLET;ORAL | 040416-006 | Oct 2, 2003 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Upsher Smith Labs | ZALEPLON | zaleplon | CAPSULE;ORAL | 078095-001 | Jun 6, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Upsher Smith Labs | QUDEXY XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 205122-001 | Mar 11, 2014 | AB2 | RX | Yes | No | 8,652,527 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Upsher Smith Labs | AZELASTINE HYDROCHLORIDE | azelastine hydrochloride | SPRAY, METERED;NASAL | 202609-001 | Mar 17, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Upsher Smith Labs | FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride | TABLET;ORAL | 211696-001 | Jan 30, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Upsher Smith
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE43580 | ⤷ Try a Trial |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | 6,440,392 | ⤷ Try a Trial |
| Upsher Smith Labs | FORTICAL | calcitonin salmon recombinant | SPRAY, METERED;NASAL | 021406-001 | Aug 12, 2005 | RE40812 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for UPSHER SMITH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg | ➤ Subscribe | 2015-12-24 |
| ➤ Subscribe | Nasal Spray | 200 IU/spray | ➤ Subscribe | 2006-03-29 |
International Patents for Upsher Smith Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3079703 | ⤷ Try a Trial |
| Brazil | 112015022434 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2014143380 | ⤷ Try a Trial |
| Australia | 2014362275 | ⤷ Try a Trial |
| South Africa | 201604587 | ⤷ Try a Trial |
| Israel | 241053 | ⤷ Try a Trial |
| Canada | 2857286 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Upsher Smith Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1409467 | 92717 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121 |
| 1409467 | C300738 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
| 1713823 | 92595 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516 |
| 0186405 | SPC/GB00/021 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316 |
| 0382526 | 19675032 | Germany | ⤷ Try a Trial | PRODUCT NAME: LAMIVUDINE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH GEEIGNETEN SALZES; NAT. REGISTRATION NO/DATE: EU/1/96/015/001-002 19960808 FIRST REGISTRATION: CH 53662 53663 19960228 |
| 2317997 | 2190050-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
| 2666774 | CR 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
